US4427651A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Enriched plasma derivative for enhancement of wound closure and coverage
Assignee: SERAPHARM & Co KG AN FRG CORP GmbH
•
Filing: 1982-06-07
•
Granted: 1984-01-24
•
Expires: 2002-06-07
Abstract
Abstract A sprayable preparation for accelerated hemostasis and optimized biochemical control of wound closure contains a powdery mixture of 15 to 60% by weight of thrombin, 5 to 80% by weight of a desiccating and stabilizing agent, viz., albumin, globulin and/or fibrinogen, and 1 to 10% by weight of a fibrinolysis inhibitor. The powdery mixture is suspended in a low-boiling, anhydrous solvent, which is used as a propellant. For effective wound closure and coverage, a spray jet of this suspension is directed onto the wound under evaporation of the solvent so that substantially only the dry, solid powdery mixture reaches the wound. This method of application by spraying is also disclosed.
Inventors
- 👤 Michael Stroetmann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:17
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/225; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/16; A61K35/19; A61K38/00; A61K38/16; A61K38/17; A61K38/36; A61K38/363; A61K38/37; A61K38/38; A61K38/39; A61K38/43; A61K38/46; A61K38/48; A61K38/482; A61K38/4833; A61K38/4846; A61K45/00; A61K45/06; A61L24/00; A61L24/04; A61L24/10; A61L24/102; A61L24/106; A61L24/108; A61L26/00; A61L26/0009; A61L26/0028; A61L26/0033; A61L26/0042; A61L26/0057; A61L26/0061; A61L26/0066; A61F; A61F2310/00; A61F2310/00005; A61F2310/00365; A61F2310/00377; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/40; A61L2300/404; A61L2300/406; A61L2300/418; A61L2300/432; A61L2300/434; A61L2400/00; A61L2400/04; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
48 words
An enriched plasma derivative composition useful for accelerated hemostasis and optimized control of wound closure, consisting essentially of thrombin, a desiccating and stabilizing agent, and a fibrinolysis inhibitor, the constituents of the composition being in powdery state, and said composition being in the form of a sprayable admixture.
Claim 2
Dependent Claim
48 words
An enriched plasma derivative composition useful for accelerated hemostasis and optimized control of wound closure, consisting essentially of thrombin, a desiccating and stabilizing agent, and a fibrinolysis inhibitor, the constituents of the composition being in powdery state, and said composition being in the form of a sprayable admixture.
Claim 3
Dependent Claim
21 words
A plasma derivative composition as claimed in claim 1, comprising fibrinogen, thrombin, components of the prothrombin complex, and a protease inhibitor.
Claim 4
Dependent Claim
21 words
A plasma derivative composition as claimed in claim 1 or claim 2, comprising also a blood platelet extract or an antibiotic.
Claim 5
Dependent Claim
123 words
An enriched plasma derivative composition of claim 1, for enhancement of wound or operation area closure and coverage, based on human plasma derivatives containing thrombin and a fibrinolysis inhibitor, consisting essentially of a powdery admixture of the following: 15 to 60% by weight of thrombin; 5 to 80% by weight of a desiccating and stabilizing agent selected from albumin, globulin, and fibrinogen; and 1 to 10% by weight of a fibrinolysis inhibitor (respectively based on the weight of the powder) suspended in a low-boiling anhydrous solvent as propellant, said suspension being adapted to permit direction of a spray jet thereof onto a wound with concurrent evaporation of the solvent so that substantially only the dry solid powdery mixture reaches the wound or area.
Claim 6
Dependent Claim
19 words
A plasma derivative composition as claimed in claim 4, wherein a part of the thrombin is replaced by prothrombin.
Claim 7
Dependent Claim
21 words
A plasma derivative composition as claimed in claim 5, wherein the powdery mixture contains 5 to 40% by weight of prothrombin.
Claim 8
Dependent Claim
29 words
A plasma derivative composition as claimed in any of claims 4, 5, or 6, wherein the powdery mixture additionally contains 2 to 24% by weight of powdery, water-soluble collagen.
Claim 9
Dependent Claim
28 words
A plasma derivative composition as claimed in any of claims 4, 5, or 6, wherein the powdery mixture additionally contains 0.2 to 2% by weight of platelet extract.
Claim 10
Dependent Claim
71 words
A plasma derivative composition as claimed in claim 1 or 4, wherein the powdery mixture consists essentially of 20 to 50% by weight of thrombin 5 to 40% by weight of prothrombin 8 to 70% by weight of an agent selected from albumin, globulin, and fibrinogen 3 to 12% by weight of water-soluble collagen 0.5 to 1.2% by weight of platelet extract, and 2 to 6 by weight of fibrinolysis inhibitor.
Claim 11
Dependent Claim
36 words
A plasma derivative composition as claimed in any of claims 1, 4, or 9, wherein the powdery mixture additionally contains 1 to 10 units of factor VIII or factor IX per 1 g of powdery mixture.
Claim 12
Dependent Claim
24 words
A plasma derivative composition as claimed in any of claims 1, 4, or 9, wherein the powdery mixture additionally contains a bactericide or antibiotic.
Claim 13
Dependent Claim
30 words
A plasma derivative composition as claimed in any of claims 1, 4, or 9, wherein the powdery mixture has an average particle size ranging between 0.1 μm and 5 μm.
Claim 14
Dependent Claim
37 words
A plasma derivative composition as claimed in any of claims 1, 4, or 9, wherein a solvent propellant is employed and wherein the solvent used as the propellant boils below 10° C. at atmospheric pressure (100 kPa).
Claim 15
Dependent Claim
21 words
A plasma derivative composition as claimed in claim 13, wherein the solvent used as the propellant is an aliphatic halogenated hydrocarbon.
Claim 16
Dependent Claim
30 words
A plasma derivative composition as claimed in claim 14, wherein the aliphatic halogenated hydrocarbon is tetrafluorodichloro-ethane (C 2 F 4 Cl 2 ) or difluorodichloromethane (CF 2 Cl 2 ).
Claim 17
Dependent Claim
69 words
Method of treating a wound or the area of an operation comprising the step of applying an enriched plasma derivative composition thereto, by spraying, to effect accelerated hemostasis and optimized control of wound closure, said composition consisting essentially of thrombin, a desiccating and stabilizing agent, and a fibrinolysis inhibitor, the constituents of the composition being in powdery state, and said composition being in the form of a sprayable admixture.
Claim 18
Dependent Claim
69 words
Method of treating a wound or the area of an operation comprising the step of applying an enriched plasma derivative composition thereto, by spraying, to effect accelerated hemostasis and optimized control of wound closure, said composition consisting essentially of thrombin, a desiccating and stabilizing agent, and a fibrinolysis inhibitor, the constituents of the composition being in powdery state, and said composition being in the form of a sprayable admixture.
Claim 19
Dependent Claim
34 words
Method of claim 16, wherein the composition is a sprayable admixture according to claim 4, and wherein, due to concurrent evaporation of solvent, substantially only the dry solid mixture reaches the wound or area.
Claim 20
Dependent Claim
14 words
Method of claim 17, wherein the composition sprayed is a composition of claim 9.
Claim 21
Dependent Claim
14 words
Method of claim 17, wherein the composition sprayed is a composition of claim 14.
Claim 22
Dependent Claim
14 words
Method of claim 17, wherein the composition sprayed is a composition of claim 15.
References Cited (Backward Citations)
US4298598A
Cited
US4362567A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-01-23 | 1987-07-25 | 1988-01-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-01-23 | 1991-07-25 | 1992-01-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-01-23 | 1995-07-25 | 1996-01-24 | $7700.00 | Window Closed / Lapsed |